Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
Next-generation gene editing powers new hope for hard-to-treat solid tumors in early human trials.
A pivotal step forward for Duchenne families as gene therapy shows promise to transform neuromuscular care.
While VC investment cools, innovative startups find new ways to fuel biotech innovation and clinical progress.
A historic breakthrough as the first CRISPR-based gene-editing therapy gains FDA approval, offering new hope for sickle cell …
A landmark Australian trial will test olfactory cell transplantation combined with intensive rehab to restore function in chronic …
With fresh capital and a new pipeline strategy, Replicor aims to tackle chronic viral infections and rare liver …
ExoGene’s novel delivery platform earns RMAT status for its lead candidate EXG-401, targeting neuroinflammation and motor neuron survival …
Personalized mRNA cancer vaccine combined with Keytruda delivers sustained recurrence-free survival in high-risk melanoma patients, reinforcing immunotherapy’s future.